Your browser doesn't support javascript.
loading
Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function.
Hwang, Mark E; Mayeda, Mark; Shaish, Hiram; Elliston, Carl D; Spina, Catherine S; Wenske, Sven; Deutsch, Israel.
Afiliação
  • Hwang ME; Department of Radiation Oncology, University of Wisconsin Health Cancer Center at ProHealth Care, Waukesha, WI, USA.
  • Mayeda M; Department of Radiation Oncology, Columbia University Medical Center, New York, NY, USA.
  • Shaish H; Department of Radiology, Columbia University Medical Center, New York, NY, USA.
  • Elliston CD; Department of Radiation Oncology, Columbia University Medical Center, New York, NY, USA.
  • Spina CS; Department of Radiation Oncology, Columbia University Medical Center, New York, NY, USA.
  • Wenske S; Department of Urology, Columbia University Medical Center, New York, NY, USA.
  • Deutsch I; Department of Radiation Oncology, Columbia University Medical Center, New York, NY, USA.
Br J Radiol ; 94(1119): 20200433, 2021 Mar 01.
Article em En | MEDLINE | ID: mdl-33586999
ABSTRACT

OBJECTIVE:

We aim to test the hypothesis that neurovascular bundle (NVB) displacement by rectal hydrogel spacer combined with NVB delineation as an organ at risk (OAR) is a feasible method for NVB-sparing stereotactic body radiotherapy.

METHODS:

Thirty-five men with low- and intermediate-risk prostate cancer who underwent rectal hydrogel spacer placement and pre-, post-spacer prostate MRI studies were treated with prostate SBRT (36.25 Gy in five fractions). A prostate radiologist contoured the NVB on both the pre- and post-spacer T2W MRI sequences that were then registered to the CT simulation scan for NVB-sparing radiation treatment planning. Three SBRT treatment plans were developed for each patient (1) no NVB sparing, (2) NVB-sparing using pre-spacer MRI, and (3) NVB-sparing using post-spacer MRI. NVB dose constraints include maximum dose 36.25 Gy (100%), V34.4 Gy (95% of dose) <60%, V32Gy <70%, V28Gy <90%.

RESULTS:

Rectal hydrogel spacer placement shifted NVB contours an average of 3.1 ± 3.4 mm away from the prostate, resulting in a 10% decrease in NVB V34.4 Gy in non-NVB-sparing plans (p < 0.01). NVB-sparing treatment planning reduced the NVB V34.4 by 16% without the spacer (p < 0.01) and 25% with spacer (p < 0.001). NVB-sparing did not compromise PTV coverage and OAR endpoints.

CONCLUSIONS:

NVB-sparing SBRT with rectal hydrogel spacer significantly reduces the volume of NVB treated with high-dose radiation. Rectal spacer contributes to this effect through a dosimetrically meaningful displacement of the NVB that may significantly reduce RiED. These results suggest that NVB-sparing SBRT warrants further clinical evaluation. ADVANCES IN KNOWLEDGE This is a feasibility study showing that the periprostatic NVBs can be spared high doses of radiation during prostate SBRT using a hydrogel spacer and nerve-sparing treatment planning.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Planejamento da Radioterapia Assistida por Computador / Radiocirurgia / Hidrogéis / Disfunção Erétil Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male Idioma: En Revista: Br J Radiol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Planejamento da Radioterapia Assistida por Computador / Radiocirurgia / Hidrogéis / Disfunção Erétil Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male Idioma: En Revista: Br J Radiol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos